| Identification | Back Directory | [Name]
QGC583 | [CAS]
2417001-25-1 | [Synonyms]
QGC583
Butanoic acid, 4-amino-4-[hydroxy[2-(2-methoxyphenyl)ethyl]phosphinyl]-, (4R)- | [Molecular Formula]
C13H20NO5P | [MOL File]
2417001-25-1.mol | [Molecular Weight]
301.28 |
| Chemical Properties | Back Directory | [Boiling point ]
605.7±55.0 °C(predicted) | [density ]
1.295±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
2.27±0.50(predicted) |
| Hazard Information | Back Directory | [Uses]
QGC583 is an effective selective Aminopeptidase A (APA) inhibitor with oral activity and blood-brain barrier permeability, boasting an IC50 value of 4 nM. QGC583 can inhibit APA activity in the brain, kidneys, and heart of rats[1]. | [in vivo]
QGC583 (2 mg/kg; i.v.; single dose) reduces APA activity in the heart, kidneys, and brain of rats by 78%, 66%, and 71% respectively[1]. | [References]
[1] Balavoine F, et al. Rational design, synthesis and pharmacological characterization of novel aminopeptidase A inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2024, 113: 129940. DOI:10.1016/j.bmcl.2024.129940 |
|
|